ct引导下射频消融与靶向治疗对肺癌患者干预疗效及生存率的比较研究。

IF 1.1 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Current Medical Imaging Reviews Pub Date : 2025-01-02 DOI:10.2174/0115734056311827241211092432

Tianyu Zhao, Chunjing Zhang, Hang Dai, Jingyu Li, Liguo Hao, Yanan Liu

{"title":"ct引导下射频消融与靶向治疗对肺癌患者干预疗效及生存率的比较研究。","authors":"Tianyu Zhao, Chunjing Zhang, Hang Dai, Jingyu Li, Liguo Hao, Yanan Liu","doi":"10.2174/0115734056311827241211092432","DOIUrl":null,"url":null,"abstract":"Objective: The study aims to evaluate the clinical efficacy of CT-guided radiofrequency ablation in conjunction with targeted therapy in lung cancer patients.Method: We retrospectively analyzed 80 lung cancer patients. They were stratified into the Observation Group (OG, n=40, treated with CT-guided radiofrequency ablation in conjunction with targeted therapy) and the Control Group (CG, n=40, treated solely with targeted therapy).Results: The OG group reported 4 cases of Complete Response (CR), 24 cases of Partial Response (PR), 10 cases of Stable Disease (SD), and 2 cases of Progressive Disease (PD). The Overall Response Rate (ORR) was 70.00% (28/40), and the Disease Control Rate (DCR) was 95.00% (38/40). In contrast, the CG group exhibited 3 cases of CR, 20 cases of PR, 12 cases of SD, and 5 cases of PD. The ORR was 57.50% (23/40), and the DCR was 87.50% (35/40). The ORR and DCR in the OG group were significantly higher than those in the CG group. After 6 weeks of treatment, the levels of SCC, CEA, and CA125 in the OG group were significantly lower than those in the CG group; The CD4+ levels in the OG group were significantly higher and the CD8+ levels significantly lower than those in the CG group. A 24-month follow-up showed that the survival rate of the OG group was 47.50% (19/40), which was significantly higher than that of the CG group at 27.50% (11/40).Conclusion: CT-guided radiofrequency ablation and targeted therapy have been proven effective in treating lung cancer.","PeriodicalId":54215,"journal":{"name":"Current Medical Imaging Reviews","volume":" ","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Comparative Study of CT-Guided Radiofrequency Ablation and Targeted Therapy: Intervention Efficacy and Survival Rates in Lung Cancer Patients.\",\"authors\":\"Tianyu Zhao, Chunjing Zhang, Hang Dai, Jingyu Li, Liguo Hao, Yanan Liu\",\"doi\":\"10.2174/0115734056311827241211092432\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: The study aims to evaluate the clinical efficacy of CT-guided radiofrequency ablation in conjunction with targeted therapy in lung cancer patients.Method: We retrospectively analyzed 80 lung cancer patients. They were stratified into the Observation Group (OG, n=40, treated with CT-guided radiofrequency ablation in conjunction with targeted therapy) and the Control Group (CG, n=40, treated solely with targeted therapy).Results: The OG group reported 4 cases of Complete Response (CR), 24 cases of Partial Response (PR), 10 cases of Stable Disease (SD), and 2 cases of Progressive Disease (PD). The Overall Response Rate (ORR) was 70.00% (28/40), and the Disease Control Rate (DCR) was 95.00% (38/40). In contrast, the CG group exhibited 3 cases of CR, 20 cases of PR, 12 cases of SD, and 5 cases of PD. The ORR was 57.50% (23/40), and the DCR was 87.50% (35/40). The ORR and DCR in the OG group were significantly higher than those in the CG group. After 6 weeks of treatment, the levels of SCC, CEA, and CA125 in the OG group were significantly lower than those in the CG group; The CD4+ levels in the OG group were significantly higher and the CD8+ levels significantly lower than those in the CG group. A 24-month follow-up showed that the survival rate of the OG group was 47.50% (19/40), which was significantly higher than that of the CG group at 27.50% (11/40).Conclusion: CT-guided radiofrequency ablation and targeted therapy have been proven effective in treating lung cancer.\",\"PeriodicalId\":54215,\"journal\":{\"name\":\"Current Medical Imaging Reviews\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2025-01-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Medical Imaging Reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/0115734056311827241211092432\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Medical Imaging Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115734056311827241211092432","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

摘要

目的：评价ct引导下射频消融联合靶向治疗肺癌患者的临床疗效。方法：对80例肺癌患者进行回顾性分析。将患者分为观察组（OG, n=40，接受ct引导下射频消融联合靶向治疗）和对照组（CG, n=40，单独接受靶向治疗）。结果：OG组完全缓解（CR） 4例，部分缓解（PR） 24例，病情稳定（SD） 10例，病情进展（PD） 2例。总有效率（ORR）为70.00%(28/40)，疾病控制率（DCR）为95.00%（38/40）。CG组CR 3例，PR 20例，SD 12例，PD 5例。ORR为57.50% (23/40)，DCR为87.50%（35/40）。OG组的ORR和DCR均显著高于CG组。治疗6周后，OG组SCC、CEA、CA125水平显著低于CG组；OG组CD4+水平显著高于CG组，CD8+水平显著低于CG组。随访24个月，OG组患者生存率为47.50%(19/40)，显著高于CG组的27.50%（11/40）。结论：ct引导下射频消融和靶向治疗是治疗肺癌的有效方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A Comparative Study of CT-Guided Radiofrequency Ablation and Targeted Therapy: Intervention Efficacy and Survival Rates in Lung Cancer Patients.

Objective: The study aims to evaluate the clinical efficacy of CT-guided radiofrequency ablation in conjunction with targeted therapy in lung cancer patients.

Method: We retrospectively analyzed 80 lung cancer patients. They were stratified into the Observation Group (OG, n=40, treated with CT-guided radiofrequency ablation in conjunction with targeted therapy) and the Control Group (CG, n=40, treated solely with targeted therapy).

Results: The OG group reported 4 cases of Complete Response (CR), 24 cases of Partial Response (PR), 10 cases of Stable Disease (SD), and 2 cases of Progressive Disease (PD). The Overall Response Rate (ORR) was 70.00% (28/40), and the Disease Control Rate (DCR) was 95.00% (38/40). In contrast, the CG group exhibited 3 cases of CR, 20 cases of PR, 12 cases of SD, and 5 cases of PD. The ORR was 57.50% (23/40), and the DCR was 87.50% (35/40). The ORR and DCR in the OG group were significantly higher than those in the CG group. After 6 weeks of treatment, the levels of SCC, CEA, and CA125 in the OG group were significantly lower than those in the CG group; The CD4+ levels in the OG group were significantly higher and the CD8+ levels significantly lower than those in the CG group. A 24-month follow-up showed that the survival rate of the OG group was 47.50% (19/40), which was significantly higher than that of the CG group at 27.50% (11/40).

Conclusion: CT-guided radiofrequency ablation and targeted therapy have been proven effective in treating lung cancer.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current Medical Imaging Reviews 医学-核医学

CiteScore

2.60

自引率

0.00%

发文量

246

审稿时长

1 months

期刊介绍： Current Medical Imaging Reviews publishes frontier review articles, original research articles, drug clinical trial studies and guest edited thematic issues on all the latest advances on medical imaging dedicated to clinical research. All relevant areas are covered by the journal, including advances in the diagnosis, instrumentation and therapeutic applications related to all modern medical imaging techniques. The journal is essential reading for all clinicians and researchers involved in medical imaging and diagnosis.